<DOC>
	<DOCNO>NCT00504270</DOCNO>
	<brief_summary>This study investigate safety , efficacy pharmacokinetics R3421 patient moderate severe chronic plaque psoriasis . Patients randomize one 3 treatment group receive daily oral treatment ) R3421 20mg , b ) R3421 120mg , c ) placebo . The anticipated time study treatment &lt; 3 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study R3421 Patients With Moderate Severe Chronic Plaque Psoriasis .</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>adult patient , 1870 year age ; medically stable , moderate severe chronic plaque psoriasis . skin condition may interfere evaluation effect study medication plaque lesion ; confound concomitant condition treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>